CID1591 - Physician's Weekly


Advertisement

CID1591

MET Kinase Inhibitors Vs Sunitinib For pRCC

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. MET signaling is a key molecular driver in papillary renal cell...

Read More

Outcomes Of First-Line Immuno-Oncology Combo in mRCC

Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Using the IMDC dataset, patients treated with a 1L...

Read More

Advertisement

Advertisement

For latest news and updates
Email-id is invalid